Evaluating drug cost per response with SGLT2 inhibitors in patients with type 2 diabetes mellitus

American Health and Drug Benefits

Volumn 8, Issue 6, 2015, Pages 309-318

  Lopez, Janice M S ^a   Macomson, Brian ^a   Ektare, Varun ^b   Patel, Dipen ^b   Botteman, Marc ^b  

^a Janssen Scientific Affairs   (United States)

^b PHARMERIT INTERNATIONAL   (United States)

Author keywords

Canagliflozin; Cost per response; Dapagliflozin; Empagliflozin; HbA1c reduction; Pharmaco economics; SGLT2 inhibitors; Type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; HEMOGLOBIN A1C; METFORMIN; PLACEBO; SULFONYLUREA;

ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; HUMAN; INFORMATION PROCESSING; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS;

EID: 84944318704     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. 2014. www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed September 11, 2014.
2. Patel A, MacMahon S, Chalmers J, et al; for the ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
3. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
4. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
5. American Diabetes Association. Glycemic targets. Diabetes Care. 2015;38(suppl 1):S33-S40.
6. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36:1033-1046. Erratum in: Diabetes Care. 2013 36:1797.
7. National Committee for Quality Assurance. Proposed changes to existing measure for HEDIS1 2015: Comprehensive Diabetes Care (CDC). 2014. www.ncqa.org/Portals/0/HomePage/CDC.pdf. Accessed December 1, 2014.
8. Centers for Medicare & Medicaid Services. Medicare Shared Savings Program quality measure benchmarks for the 2015 reporting year. www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/sharedsavingsprogram/Downloads/­MSSP-QM-Benchmarks-2015.pdf. Accessed August 17, 2015.
9. Catalyst for Payment Reform. National Scorecard on Payment Reform. 2014. www.catalyzepaymentreform.org/images/documents/nationalscorecard2014.pdf. Accessed November 27, 2014.
10. National Committee for Quality Assurance. HEDIS & performance measurement: measuring performance. www.ncqa.org/tabid/59/Default.aspx. Accessed August 17, 2015.
11. Lafeuille M-H, Grittner AM, Gravel J, et al. Quality measure attainment in patients with type 2 diabetes mellitus. Am J Manag Care. 2014;20(1 suppl):S5-S15.
12. Stephens JM, Botteman MF, Hay JW. Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. J Manag Care Pharm. 2006;12:130-142.
13. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010 27:136-142.
14. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14:5-14.
15. Berhan A, Barker A. Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. BMC Endocr Disord. 2013;13:58.
16. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium–glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262-274.
17. Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010 33:2217-2224.
18. Roden M, Weng J, Eilbracht J, et al; for the EMPA-REG MONO Trial Investigators. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1:208-219.
19. Stenlöf K, Cefalu WT, Kim K-A, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372-382.
20. Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36:2154-2161.
21. Sha S, Polidori D, Farrell K, et al. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study. Diabetes Obes Metab. 2015;17:188-197.
22. Tyler LS, Cole SW, May JR, et al; for the ASHP Expert Panel on Formulary Management. ASHP Guidelines on the Pharmacy and Therapeutics Committee and the Formulary System. Am J Health Syst Pharm. 2008;65:1272-1283.
23. Belozeroff V, Lee A, Tseng S, et al. Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcet. J Med Econ. 2013;16:1154-1162.
24. Liu Y, Wu EQ, Bensimon AG, et al. Cost per responder associated with biologic therapies for Crohn’s disease, psoriasis, and rheumatoid arthritis. Adv Ther. 2012;29:620-634.
25. RED BOOK Online. Truven Health Analytics; 2015. http://sites.truvenhealth.com/redbook/online/. Accessed February 8, 2015.
26. Farxiga (dapagliflozin) tablets [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; March 2015.
27. Invokana (canagliflozin) tablets [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; March 2015.
28. Jardiance (empagliflozin) tablets [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; June 2015.
29. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223-2233.
30. Häring H-U, Merker L, Seewaldt-Becker E, et al; for the EMPA-REG MET Trial Investigators. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37:1650-1659.
31. Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582-2592.
32. Häring H-U, Merker L, Seewaldt-Becker E, et al; for the EMPA-REG METSU Trial Investigators. Empagliflozin as add-on to metformin plus sulfonyl­urea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013;36:3396-3404.
33. Matthaei S, Bowering K, Rohwedder K, et al; for the Study 05 Group. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care. 2015;38:365-372.
34. Wilding JPH, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013 67:1267-1282.
35. Pacou M, Taieb V, Abrams KR, et al. Bayesian network meta-analysis to assess relative efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin. Value Health. 2013;16. Abstract PRM193.
36. Pacou M, Taieb V, Abrams KR, et al. Bayesian network meta-analysis to assess the relative efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and sulphonylurea (MET+SU). Value Health. 2013;16. Abstract PDB2.
37. Kirson NY, Rao S, Birnbaum HG, et al. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis. J Med Econ. 2013;16:479-489.
38. Schechter CB, Cohen HW, Shmukler C, Walker EA. Intervention costs and cost-effectiveness of a successful telephonic intervention to promote diabetes control. Diabetes Care. 2012;35:2156-2160.